Scientific Founders
David L. Rimm, M.D. - Ph. D.
Co-Founder
Dr. David Rimm, is a Professor in the Department of Pathology at the Yale University School of Medicine. He completed an MD-PhD at Johns Hopkins University Medical School followed by a Pathology Residency at Yale and a Cytopathology Fellowship at the Medical College of Virginia. He is board certified in Anatomic Pathology and Cytopathology. At Yale since 1994, Dr. Rimm is the Director of Yale Pathology Tissue Services and the Yale Tissue Microarray Facility. He is also the Director of Medical Studies for Pathology. His lab group (15 researchers) focuses on quantitative pathology using the AQUA® technology invented in his lab with projects related to predicting response to therapy in breast cancer and predicting recurrence or metastasis in melanoma and lung cancer. He also has a group working on c-Met tyrosine kinase and group working on spectral/spatial imaging for diagnostics in cytology. He is currently supported by 9 grants from both public and private sources. He serves as a reviewer for the NIH and was a charter member of the Cancer Biomarkers Study Section. He is an editorial board member for 7 pathology journals and a member of the pathology committee for CALGB, TransALLTO and TEACH (cooperative groups or therapeutic clinical trials). He is an author of over 180 peer-reviewed papers and 6 patents and is the scientific co-founder of HistoRx, a digital pathology company and Metamark Genetics, a prognostic determinant company.
Robert L. Camp, M.D. - Ph. D.
Co-Founder
Dr. Camp is a Founder of HistoRx and is Associate Research Scientist in Pathology at Yale University
School of Medicine. An expert in quantitative pathology, Dr. Camp's research interests focus on
identifying prognostic markers in breast cancer, detecting phenotypic differences between primary
and metastatic breast cancer, growth factor responsiveness of breast carcinoma, and tissue microarrays.
His work is broadly relevant to developing advanced systems for automated analysis of immunohistochemistry.
In addition, as Director of the Program for Critical Technologies in Molecular Medicine, he oversees the
acquisition, storage, and distribution of tissue for Yale School of Medicine's Department of Pathology.
Prior to his appointment as Associate Research Scientist, Dr. Camp undertook a residency in Pathology
at Yale-New Haven Hospital, where he was selected Chief Resident in Pathology in 1999. Dr. Camp is a
named inventor on three U.S. patent applications and the author of more than 15 peer-reviewed publications.
He holds a BS from Swarthmore College, a PhD from Rockefeller University, and an MD from the Yale
University School of Medicine.